4 reports of this reaction
4.8% of all PYRANTEL PAMOATE reports
#3 most reported adverse reaction
ENTEROBIASIS is the #3 most commonly reported adverse reaction for PYRANTEL PAMOATE, manufactured by REESE PHARMACEUTICAL CO.. There are 4 FDA adverse event reports linking PYRANTEL PAMOATE to ENTEROBIASIS. This represents approximately 4.8% of all 83 adverse event reports for this drug.
Patients taking PYRANTEL PAMOATE who experience enterobiasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ENTEROBIASIS is moderately reported among PYRANTEL PAMOATE users, representing a notable but not dominant share of adverse events.
In addition to enterobiasis, the following adverse reactions have been reported for PYRANTEL PAMOATE:
ENTEROBIASIS has been reported as an adverse event in 4 FDA reports for PYRANTEL PAMOATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ENTEROBIASIS accounts for approximately 4.8% of all adverse event reports for PYRANTEL PAMOATE, making it one of the most commonly reported side effect.
If you experience enterobiasis while taking PYRANTEL PAMOATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.